News Posts List
Researchers Find New Target for Kidney Cancer Therapy
11/11/2014
Cincinnati Cancer Center (CCC) researchers have discovered that a membrane channel, Transient Receptor Potential Melastatin 3, or TRPM3, promotes growth of kidney cancer tumors, and targeting this channel therapeutically could lead to more treatments for a disease, which currently has few treatment options.
Exelixis Completes Enrollment of the METEOR Phase 3 Pivotal Trial
11/11/2014
Top-Line Data from METEOR Expected in Q2 2015
Glaxo scientists work to rebuild cancer line-up
11/06/2014
When GlaxoSmithKline agreed to sell its cancer drugs to Novartis in April, investors saw it as the death knell for an oncology business that languished well behind those of rivals.
Renal cells Carcinoma (RCC) Genome variation profiling by genome tiling array with Perkin Elmer Constituionnal Chip platform
11/06/2014
Genome variation profiling by genome tiling array
Cometriq Makes a Comeback
11/06/2014
In addition to prostate and lung cancer, Exelixis is testing Cometriq in kidney cancer and liver cancer. Data from the latter trial isn't due until 2017, but the kidney cancer trial, dubbed METEOR, is almost completely enrolled and should read out top-line results in the second quarter of next year.
Identification of Potential Serum Proteomic Biomarkers for Clear Cell Renal Cell Carcinoma
11/05/2014
To investigate discriminating protein patterns and serum biomarkers between clear cell renal cell carcinoma (ccRCC) patients and healthy controls, as well as between paired pre- and post-operative ccRCC patients.
The DART Study (a clinical trial)
11/03/2014
Dr. Voss provides details of a clinical trial that may be of interest to you. The DART study is for patients with metastatic renal cell carcinoma.
Mystery patient in medical milestone revealed
11/02/2014
First in world to have cancer tumour sequenced
Presentations from 13th International Kidney Cancer Symposium
11/02/2014
Since 1990, the Kidney Cancer Association has dedicated itself to the eradication of kidney cancer and to improving care, stimulating research, and increasing survival of kidney cancer patients worldwide. We are the only organization of its kind to serve kidney cancer patients, their families, and physicians around the world. As we work to globalize our organization, we hope to continue our collaboration with you so that we may be of further assistance to you and your patients.
Remission of psoriasis and psoriatic arthritis during bevacizumab therapy
11/01/2014
This suggests that bevacizumab might have a promising future in the treatment of psoriasis and PsA.
News Feed